Efficacy of Adjuvant Sublingual Immunotherapy After Septomeatoplasty
The Laryngoscope · 2024
DOI: 10.1002/lary.31347 ↗Kurz gefasst
Kontrollierte klinische Studie in der Zeitschrift The Laryngoscope, 2024. Verfasst von Bing-Han Hsieh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Rhinitis, Allergic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: China Medical University Hospital.
Abstract (Originalsprache)
Background
The efficacy of adjuvant sublingual immunotherapy (SLIT) in correcting structural problems in patients with allergic rhinitis (AR) caused by mite who have undergone septomeatoplasty (SMP) has not been studied.
Methods
This non‐randomized controlled study recruited patients with AR (caused by mite) and concurrent septal deviation and inferior turbinate hypertrophy, at a tertiary hospital in Taiwan. SMP was performed on all patients as a surgical intervention. The patients were then divided into two groups: the control group, which underwent surgery only, and the experimental group, which received SLIT as an adjuvant treatment. Demographic data and rhinitis control assessment test (RCAT) results were analyzed.
Results
A total of 96 patients were enrolled in the study (SMP + SLIT group, n = 52; SMP only group, n = 44). No significant differences were observed in any of the variables between the two groups before and one month after surgery. However, during evaluations at the third and sixth month, the SMP + SLIT group showed significant improvement in the total RCAT scores compared to the SMP only group (28.6 ± 1.56 vs. 24.5 ± 3.66, p < 0.001; 27.1 ± 2.87 vs. 19.9 ± 5.56, p < 0.001). In addition, significantly better control of all RCAT sub‐categories was observed in the SMP + SLIT group at the third and sixth month evaluations.
Conclusions
SLIT may serve as an ideal adjuvant therapy after SMP in patients with AR. Level of Evidence 3 Laryngoscope , 134:3073–3079, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung, Taiwan.
- Center for Allergy, Immunology, and Microbiome (A.I.M.), China Medical University Hospital, Taichung, Taiwan.
- Department of Allergy, Immunology, and Rheumatology (AIR), China Medical University Children's Hospital, Taichung, Taiwan.
- Department of Otorhinolaryngology-Head and Neck Surgery, Asia University Hospital, Taichung, Taiwan.
- School of Medicine, China Medical University, Taichung, Taiwan.
ORCID-Profile: Yung-An Tsou, Liang-Chun Shih
Förderung
- China Medical University Hospital
Zitieren
APA
Hsieh, B. H., Kuo, Y. C., Yong, S. B., Tien, H. C., Hsu, C. C., Hsu, C. L., Tsou, Y. A., Lin, C. D., Tai, C. J., Wang, J. Y., & Shih, L. C. (2024). Efficacy of Adjuvant Sublingual Immunotherapy After Septomeatoplasty. The Laryngoscope. https://doi.org/10.1002/lary.31347
Vancouver
Hsieh BH, Kuo YC, Yong SB, Tien HC, Hsu CC, Hsu CL, et al. Efficacy of Adjuvant Sublingual Immunotherapy After Septomeatoplasty. The Laryngoscope. 2024. doi:10.1002/lary.31347
BibTeX
@article{Hsieh2024,
author = {Hsieh, Bing-Han and Kuo, Yu-Chun and Yong, Su-Boon and Tien, Hui-Chi and Hsu, Chun-Chieh and Hsu, Che-Lun and Tsou, Yung-An and Lin, Chia-Der and Tai, Chih-Jaan and Wang, Jiu-Yao and Shih, Liang-Chun},
title = {Efficacy of Adjuvant Sublingual Immunotherapy After Septomeatoplasty},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31347}
}
EUVIMED